canada

canada

Trials and Noteworthy Treatments


	Treatment Next 25	Location	Last Updated

Details	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Toronto, Ontario, CANADA Bethesda, MD New York, NY Cincinnati,, OH Columbus, OH	04/21/2009

Details	A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme	Toronto, Ontario, CANADA	09/28/2008

Details	NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303	Kingston, Ontario, CANADA Edmonton, Alberta, CANADA Moncton, New Brunswick, CANADA Ottawa, Ontario, CANADA Toronto, Ontario, CANADA Winnipeg, Manitoba, CANADA Phoenix, AZ La Jolla, CA Palo Alto, CA Sacramento, CA Aurora, CO Englewood, CO Jacksonville, FL Orlando, FL Chicago, IL Evanston, IL Boston, MA Detroit, MI Winston-Salem, NC Edison, NJ Buffalo, NY Columbus, OH Columbus, OH Portland, OR Memphis, TN Nashville, TN Seattle, WA Madison, WI	03/01/2008

Details	A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients	Toronto, Ontario, CANADA	08/26/2007

Details	A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks (Pre-Surgery) on Brain Tumor O-6-Methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.	Montreal, Canada	08/18/2007

Details	Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma	Toronto, Ontario, , CANADA	05/21/2006

Details	A Phase I Study of Tomotherapy in Patients With Benign Brain Tumour	Edmonton, Alberta, Canada	05/04/2006

Details	Comparative 2-D Tumor Analysis in Familial Gliomas	Edmonton, Alberta, Canada	05/04/2006

Details	Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Gliobastoma Treated With Concurrent Radiation Therapy and Temozolomide	Edmonton, Alberta, Canada	11/27/2005

Details	FR901228 in Treating Children with Refractory or Recurrent Solid Tumors or Leukemia	, CANADA , Los Angeles, CA Palo Alto, CA Washington, DC Augusta, GA Indianapolis, IN Boston, MA Minneapolis, MN Rochester, MN Jackson, MS New York, NY Syracuse, NY Cincinnati, OH Portland, OR Portland, OR Philadelphia, PA Pittsburgh, PA Memphis, TN Dallas, TX Houston, TX San Antonio, TX Seattle, WA Marshfield, WI	11/11/2005

Details	Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors	, CANADA , Los Angeles, CA Palo Alto, CA Washington, DC Indianapolis, IN Boston, MA Minneapolis, MN Rochester, MN Jackson, MS New York, NY Syracuse, NY Cincinnati, OH Portland, OR Philadelphia, PA Pittsburgh, PA Memphis, TN Dallas, TX Houston, TX Seattle, WA	11/11/2005

News Stories

(Relevance) Question - click to see the response!
Displaying 1 to 26 of 317
Click HERE for Next 25 articles!

(Relevance) Page Title - click title to go to the page!

(0.9203) U.S. drug sales leave Canada short
Lack of two crucial drugs could affect patients with leukemia and brain tumours
(0.9115) Ecopia Named One of Canada`s Top Ten for a Second Year
(0.9017) Proxima Therapeutics Receives Canadian Medical Device Licence for New Breast Cancer Device (Canada NewsWire)
... balloon catheter that is inserted in the cavity created by surgical removal of the breast tumor....... device is designed to deliver radiation directly to the tissue surrounding the cavity, where tumors are most likely to recur....... company established in 1995 to develop site-specific cancer treatment systems for breast and brain tumors....
- Sep 25 8:30 AM ET
(0.8658) Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII...
(0.8658) Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma
(0.8658) Oncolytics Biotech Inc. announces third quarter results (Canada NewsWire)
... that the virus could kill human cancer cells derived from breast, prostate, pancreatic and brain tumors....
- Nov 07 8:37 AM ET
(0.8658) Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN(R) for the Treatment of Prostate Cancer (Canada NewsWire)
...As a secondary endpoint, the Company is measuring tumor response at both the treated lesion as well as remote metastatic sites....... cancer cells derived from many types of cancer including breast, prostate, pancreatic and brain tumours....
- Oct 11 9:06 AM ET
(0.8658) Proxima Therapeutics Receives Canadian Medical Device Licence for New Breast Cancer Device (PR Newswire)
... balloon catheter that is inserted in the cavity created by surgical removal of the breast tumor....... device is designed to deliver radiation directly to the tissue surrounding the cavity, where tumors are most likely to recur....... company established in 1995 to develop site-specific cancer treatment systems for breast and brain tumors....
- Sep 25 8:32 AM ET
(0.8511) AEterna Laboratories: Research Results Confirm Additional Mechanism of Action of its Lead Compound, Neovastat/AE-941 (Canada NewsWire)
CNW/ - AEterna Laboratories Inc., today announced new results showing that its lead product, Neovastat/AE-941, specifically activates apoptosis of endothelial cells. Previous research had also shown that Neovastat has two other mechanisms of action inhibiting matrix metalloproteinases and Vascular Endothelial Growth Factor, all aimed at stopping a cancerous tumor`s growth, by blocking the formation of new blood vessels.
- Mar 27 7:30 AM ET
(0.8511) AEterna`s Neovastat shows ability to increase the angiostatin level in mice with implanted human brain cancer cells (Canada NewsWire)
Today, AEterna Laboratories Inc. presented new data showing that Neovastat/AE-941 is able to increase the level of angiostatin in mice with implanted human glioblastoma, a form of brain cancer.
- May 14 7:30 AM ET
(0.8510) Canada OKs Schering-Plough Cancer Drug
(0.8510) Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma
(0.8510) New drug may hold answer to cancer
(0.8510) Oncolytics Biotech Inc. filing for first Phase II Clinical Trial for REOLYSIN(R) (Canada NewsWire)
...Oncolytics researchers demonstrated that reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumours successfully in a number of animal models....
- May 04 8:30 AM ET
(0.8351) Brainstorm Foundation Annual Halloween Family Dance and Activities Event this weekend - in Kingston, Ontario, Canada
(0.8351) Brain Tumour UK`s 9th Annual Patient and Carer Conference 7-8 July 2009
(0.8351) YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
(0.8351) Novel Israeli treatment zaps tumors using light and pigment
(0.8351) Oncolytics Gets OK to Start Canadian Cancer Study (Dow Jones)
CALGARY -(Dow Jones)- Oncolytics Biotech Inc. (ONCY) has received approval from Health Canada to start a Phase I/II clinical trial to investigate the use of REOLYSIN as a treatment for patients with recurrent malignant glioma, the most aggressive form of brain cancer.
- Apr 11 8:03 AM ET
(0.8351) Franzen Up for National Book Award (AP)
... 52 years old and a resident of Amherst, Mass., has had several operations for a brain tumor and has failing eyesight....
- Oct 10 8:46 PM ET
(0.8351) Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC), (NASDAQ: ONCY), will be presenting at Techvest’s 4th Annual Healthcare Conference in Boston on Tuesday, October 22 at 4:45 p.m. (EST) at the Boston Long Wharf Marriott Hotel.
(0.8351) ART Announces Acquisition of an Exclusive License to an Important Patent Portfolio in the Medical Sector (Canada NewsWire)
...which will use time domain technology to detect and diagnose breast tumors......."Acquiring the exclusive worldwide license rights to such an extensive patent portfolio will allow ART to complement its own intellectual property with respect to time domain imaging and will also assist ART to develop its SoftScan(TM) technology for other applications, including the detection and imaging of brain tumor, head injuries (hematoma) and strokes" said Paul Bisson,...
- Apr 11 6:00 AM ET
(0.8351) VSM MedTech Announces Award of MEG Contract by Top-Five Neuro Hospital in U.S.
(0.8351) Nycomed Amersham Imaging and Neurochem collaborate to create Alzheimer`s diagnostic (Canada NewsWire)
... presence of amyloid plaques that accumulate in the brains of Alzheimer`s patients....... products, some of which are used to treat localized tumors such as prostate cancer,...
- Jul 19 8:01 AM ET
(0.8351) Primitive neuroectodermal tumors in the central nervous system following cranial irradiation: A report of four cases

Frequently Asked Questions

(Relevance) Question - click to see the response!
Displaying 1 to 7 of 7

  (0.7967) My father (78 years old, no other history of illness and no other cancer) has been given a preliminary diagnosis of GBM. The tumor is in the temporal lobe and the size of a grape. There is no neuro-oncologist at this hospital. Should we go through with removal and then seek a second opinion once we have a diagnosis based on a tissue sample? My father seems convinced that there are no treatment options that could be effective considering the size of the tumour.

  (0.7967) My 78 year old mother has just been dx with GBM 4. She has been seen by a neurosurgeon who was very blunt and said you have lived a good life. He said we could try debulking. We left feeling as if nothing could be gained. I have contacted the Brain Tumor CLinic at Duke and they currently have her MRI pics. I haven~t yet heard from them and I am afraid that time is of the essence. I cannot just sit back and watch this beautiful and much loved woman slip away. We are in Canada and I wondered if you knew someplace that we might approach for another consult. Our neurologist is very kind and agreeable to anything we might choose to do. Please advise, Cynthia

  (0.7967) Until recently I was covered for Prescription Medication by the A & P Group coverage here in Ontario. For some reason the company has decided to create a clause in it~s newly signed contract that has overlooked by the C.A.W. Union. This puts me in a very difficult position. I have a 2nd grade Oliogodendroglioma in the right frontal lobe that causes a great deal of focal seizures. I have been taking dilantin 400mg at bed time, and 2700mg of Neurontin spread over 3 doses a day. The Neurontin is so expensive that I can no longer buy my medication. I have 1 weeks supply left so I need to find another medication to replace the Neurontin that costs a lot less but will help with the seizures. Because I have a lot of health conditions it is difficult to prescribe something that will help me. I have tried to contact my Neurologist regarding this matter but have had no reply in 2 weeks. Can you suggest another medication for me. I will see my M.D. on Thursday of this week and if I know of a drug to suggest to him he will write a prescription for this. Unfortunately he does not have a lot of experience with Brain Tumors, or the medications that will control the seizures. I am very desperate now and need an answer quickly. Please except my gratitude for responding as quickly as you can. Shirley A. Sciberras 241 Andrew Street Shelburne Ontario Canada L0N 1S4 (519) 925-2361

  (0.7742) URGENT: Please inform as soon as possible; we have to decide whether we (Sharon Mussen, a 35 year-old social worker, accompanied by one or both parents) should go to Germany for treatment of a high-grade oligoastrocytoma, which has advanced from Grade 2 in 2000, to Grade 3 in 2004, to probably Grade 4 currently. We are awaiting the pathology analysis of the regrown tumor tissue resected last month. It is of life-threatening urgency because the growth seems to be accelerating. Can the receiver of this note, or some other brain tumor physician or researcher to whom you may refer this difficult question, provide us with good OBJECTIVE information and an opinion, very quickly, about the effectiveness of the treatment performed by Dr. Klaus Maier-Hauff (and his clinic at Berlin's Charite Hospital) where it is claimed that a brain-tumor will absorb an applied dosage of sub-microscopic, magnetic, iron-oxide particles which, if we understand correctly, heat and weaken or destroy tumor cells (with no permanent damage to healty tissue or the brain-centered faculties of language, memory, motor/movement, etc). The method has been variously described as Nanotechnology, Nanopartical Application, Thermotherapy, and perhaps other descriptive names. The literature that we have found (mostly at their web-site) is put out by the clinic and/or the German government information services. There is mention, in their web-site literature, of research that is on-going or scheduled to begin. But, even if rigorous medical research has not as yet been completed,we want to base our decision on at least the opinion of knowledgable, non-involved experts. A well-known neurosurgeon here dismissed the idea by telling us that "we tried that method some years ago and found it did not work"; however, as you and we know, nanotechnology is relatively new and, therefore, rapidly improving. Again we need expert, objective opinion. A brief review of the medical situation: In the year 2000, Sharon suffered a grand mal seizure; was taken to

  (0.7742) My sister was diagnosed with a GBM on her right frontal lobe. She had a craniotomy to remove the tumor but the neurosurgeon said that he was only able to remove about 80% because, when he got in, he noticed that it had crossed the midline. It has been seven weeks since her surgery and she just now started radiation and Temodar. She was developing headaches again and double vision so they took another MRI and it shows that the tumor has grown back. What do they mean by the tumor has crossed the midline? Does this mean that it is inoperable? Can't surgery be performed on each side of the lobe to remove as much as possible? The surgeon never ordered an MRI after the surgery so we really do not know how much was really taken. Is this normal?

  (0.7742) My father has glioblastoma and the oncologist is suggesting starting the standard round of 30 radiotherapy treatments (following the surgery). It was a 2.5 cm tumor that was mostly removed from the surface of the right frontal lobe. IMRT is not available in our Canadian province. Would radiotherapy using IMRT versus the traditional radiotherapy approach be beneficial for my father in terms of tumor management, and more so in terms of possible side effects? We are debating if we should try to ask for a referral to a center in a different province that does have IMRT available (we are in Canada, so our medical system is a bit different than the states).

  (0.7742) Thank you for your reply to my question re treatment Oligo/Asto.II - Is it your opinion that surgery if it is possible is best in the first instance. I note from letter from others that as soon as surgery is done the tumour usually changes to a more agressive type - or am I wrong? My tumour size is big 5.5x 5.5cm My neurosurgen said that surgery is to releave symtons only and as I had none I should not risk dangerous surgery. He had been going to operate l998 when the tumour was at the Superior Temporal Gyrus. unforturnately this op had to be cancelled as my husband took ill and later died. So surgery was put off by my surgeon saying there was no change and doing yearly scans, until Sept. 2001. The MRI showed small focali contrast enhancement in the depth paticularly of the posturo temporal and parietal foci. He was sure it had turned anaplastic I also started having a metalic taste in my mouth from time to time. He ordered a biopsy (my first) December 2001 but this showed no anaplasia and still a low grade Tumour. The took 17 biopsies but did not have the technoclogy to test for chemo agents. I have had three opinions on treatment. Chemo- PCV from Liverpool. London - It could be helped by chemo but it would take a long time, therefore radiotherapy. Edinburgh standard treatment radiotherapy. I have an appointment in Glasgow next Tuesday. I feel that radiotherapy is effective in fast growing tumours but is there any evidence that it is effective in low grades. Steriotactic radiotherapy may be no use as mine is too large.Thank you once again for your reply I am impressed.

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By